NASDAQ · NEO
Healthcare · Medical - Diagnostics & Research
$16.84
Up+$0.35 (+2.12%)
Updated Nov 7, 2026, 9:46 AM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · NEO
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 6, 2026
NEO closed at $16.84 after 21 trading sessions, up 3.00% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 6, 2026 | $16.85 | $16.93 | $16.12 | $16.84 | 1.31M |
| Nov 5, 2026 | $16.90 | $16.90 | $15.90 | $16.49 | 2.11M |
| Nov 4, 2026 | $17.26 | $17.39 | $16.60 | $17.15 | 1.15M |
| Nov 3, 2026 | $16.65 | $17.34 | $16.565 | $16.83 | 1.81M |
| Nov 2, 2026 | $17.66 | $17.66 | $16.2902 | $16.49 | 1.71M |
| Oct 30, 2026 | $17.95 | $18.15 | $17.09 | $17.38 | 1.46M |
| Oct 29, 2026 | $17.25 | $18.15 | $16.83 | $17.93 | 3.76M |
| Oct 28, 2026 | $17.30 | $18.03 | $17.25 | $17.99 | 2.58M |
| Oct 27, 2026 | $16.91 | $17.48 | $16.69 | $17.27 | 2.75M |
| Oct 26, 2026 | $16.62 | $17.00 | $16.61 | $16.69 | 1.3M |
| Oct 23, 2026 | $16.36 | $16.755 | $16.065 | $16.59 | 1.43M |
| Oct 22, 2026 | $16.89 | $17.1747 | $16.125 | $16.39 | 2.46M |
| Oct 21, 2026 | $16.62 | $17.30 | $16.54 | $17.04 | 1.49M |
| Oct 20, 2026 | $16.55 | $16.92 | $16.39 | $16.62 | 1.1M |
| Oct 19, 2026 | $16.90 | $17.17 | $16.39 | $16.42 | 1.33M |
| Oct 16, 2026 | $17.24 | $17.45 | $16.44 | $16.65 | 2.31M |
| Oct 15, 2026 | $17.00 | $17.335 | $16.61 | $17.25 | 1.32M |
| Oct 14, 2026 | $16.49 | $17.25 | $16.445 | $16.88 | 1.62M |
| Oct 13, 2026 | $16.30 | $16.98 | $15.9796 | $16.66 | 2.24M |
| Oct 12, 2026 | $16.35 | $16.35 | $15.86 | $16.20 | 1.18M |
| Oct 9, 2026 | $16.02 | $16.655 | $16.00 | $16.35 | 1.39M |
The latest Smart Investors Daily articles mentioning NEO.
Company
Market Activity
Research & News
NEO research
Company profile and research snapshot.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 29, 2026 | BTIG | Buy | — |
| Oct 29, 2026 | TD Cowen | Buy | — |
| Oct 6, 2026 | BTIG | Buy | — |
| Oct 6, 2026 | StoneX | Buy | — |
| Oct 6, 2026 | Needham | Buy | — |
No generated briefing is available yet.
Yahoo · Nov 3, 2026
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) announced better-than-expected revenue in Q3 2026, with sales up 11.4% year on year to $209.3 million. The company expects the full year’s revenue to be around $808 million, close to analysts’ estimates. Its non-GAAP profit of $0.07 per share was 26.2% above analysts’ consensus estimates.
Yahoo · Oct 31, 2026
NeoGenomics delivered an 11.4% year-over-year revenue increase in Q3, surpassing Wall Street’s expectations. Management emphasized that clinical revenue growth was primarily fueled by strong adoption of next-generation sequencing (NGS) tests and ongoing improvements in average price per test, aided by a strategic shift away from low-margin, high-volume contracts. CEO Anthony Zook highlighted that “NGS revenue grew a strong 29%,” attributing margin expansion to a higher mix of advanced tests and
SeekingAlpha · Oct 30, 2026
2026-10-30. The following slide deck was published by NeoGenomics, Inc.
Yahoo · Oct 29, 2026
NeoGenomics (NEO) just delivered third quarter 2026 results that topped expectations, with double digit year over year revenue growth, improved adjusted earnings guidance, and a planned CEO transition that reshapes the leadership picture. NeoGenomics’ latest earnings surprise has arrived after a powerful run, with the share price delivering a 52.98% year to date share price return and a 75.00% total shareholder return over one year, even though the 5 year total shareholder return is still...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NEO.
